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Abstract
Preeclampsia, a pregnancy-specific syndrome characterized by hypertension, proteinuria and edema, is a major cause of
fetal and maternal morbidity and mortality especially in developing countries. Bj-PRO-10c, a proline-rich peptide isolated
from Bothrops jararaca venom, has been attributed with potent anti-hypertensive effects. Recently, we have shown that Bj-
PRO-10c-induced anti-hypertensive actions involved NO production in spontaneous hypertensive rats. Using in vitro studies
we now show that Bj-PRO-10c was able to increase NO production in human umbilical vein endothelial cells from
hypertensive pregnant women (HUVEC-PE) to levels observed in HUVEC of normotensive women. Moreover, in the
presence of the peptide, eNOS expression as well as argininosuccinate synthase activity, the key rate-limiting enzyme of the
citrulline-NO cycle, were enhanced. In addition, excessive superoxide production due to NO deficiency, one of the major
deleterious effects of the disease, was inhibited by Bj-PRO-10c. Bj-PRO-10c induced intracellular calcium fluxes in both,
HUVEC-PE and HUVEC, which, however, led to activation of eNOS expression only in HUVEC-PE. Since Bj-PRO-10c promoted
biological effects in HUVEC from patients suffering from the disorder and not in normotensive pregnant women, we
hypothesize that Bj-PRO-10c induces its anti-hypertensive effect in mothers with preeclampsia. Such properties may initiate
the development of novel therapeutics for treating preeclampsia.
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Introduction
Preeclampsia, a pregnancy-specific syndrome characterized by
hypertension, proteinuria and edema, causes fetal and maternal
morbidity and mortality with high incidence in developing
countries [1]. Symptoms of preeclampsia are currently combated
by sodium restriction, rest and medication for blood pressure
control to avoid complications for the mother and prolong the
pregnancy for fetal maturation [2–4]. However, this attempt is
rather unspecific with possible side effects for the developing fetus
[5–7]. Currently, the only therapy of preeclamsia involves placenta
removal resulting in pre-term birth [8]. Therefore, novel drug
development for pregnancy-specific conditions remains a chal-
lenge [7]. Our current knowledge is that hypertension in
preeclampsia is secondary to placental underperfusion. Thus,
therapeutic reduction of systemic blood pressure is not believed to
reverse the primary pathogenic process, and antihypertensive
medication has never been demonstrated to cure or reverse
preeclampsia [3].
The pathology of preeclampsia has been characterized by
systemic inflammation, oxidative stress, alterations in the levels of
angiogenic factors, and vascular reactivity leading to hypertension
of the mother and metabolic alterations in the fetus [8,9]. A
number of evidence suggests that the clinical manifestations are
caused by endothelial malfunction including insufficient produc-
tion of nitric oxide (NO) [10,11]. NO production originates from
the action of endothelial nitric oxide synthase (eNOS), a Ca2+-
dependent enzyme, using L-arginine as substrate [12]. This
gaseous messenger then diffuses from endothelial cells to vascular
smooth muscle thus providing a dilator tone [13]. It has been
suggested that the concentration of L-arginine in the pregnant
plasma, activity and levels of eNOS which is constitutively
expressed, but not the inducible NOS are altered in endothelial
cells and play critical roles in pathogenesis of preeclampsia
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including vascular stress and inflammatory processes [9,14,15],
since the low availability of L-arginine uncouples eNOS activity,
decreases NO production and increases eNOS-dependent super-
oxide generation [9,15]. Therefore, it is expected that the
sustained concentration of L-arginine in endothelial cells is likely
to play a critical role not only in the control of systemic blood
pressure but also in inhibition of inflammatory processes [16,17].
A family of pyroglutamyl proline-rich oligopeptides has been
isolated from the venom gland of the pit viper Bothrops jararaca (Bj-
PROs) and many of those showed strong bradykinin-potentiating
activity. Recent results indicated the targets of Bj-PRO-10c,
resulting in neurotransmitter release, NO production and
alteration of baroreflex control, resulting in alteration of arterial
pressure and heart rate [18,19].
Our group has recently demonstrated that Bj-PRO-10c
augments the L-arginine levels ex vivo and in vivo, due to activation
of argininosuccinate synthase (ASS), a rate limiting enzyme in L-
arginine biosynthesis in the NO-citrulline cycle for NO production
in the endothelium [20].
In view of the absence of molecular targets for combating
preeclampsia which would allow to control arterial pressure levels
in hypertensive pregnant without the risk of inducing sharp drops
in blood pressure and heart rate of the fetus, we have investigated
in the present study, whether the anti-hypertensive activity of
peptide Bj-PRO-10c would correct dysfunction of human
umbilical vein endothelial cells from pregnant women suffering
from preeclampsia (HUVEC-PE). In fact, in the presence of Bj-
PRO-10c NO production by HUVEC-PE was similar to HUVEC
from normotensive pregnants. Together with augmented NO
production, bioavailability of L-arginine for eNOS re-coupling
increased, leading to decreased superoxide generation and turning
Bj-PRO-10c into a promising tool for preeclampsia resulting from
disturbed NO metabolism.
Results
Bj-PRO-10c-induced NO production by HUVEC-PE
Basal NOx production by HUVEC was twice higher than
compared to HUVEC-PE (Figure 1), supporting the hypothesis
that NO deficiency is involved in the pathophysiology of
preeclampsia [10,11]. In another study [19], we have shown that
Bj-PRO-10c-induced anti-hypertensive actions involved NO
production in spontaneous hypertensive rats. Therefore, we
studied the effects of various Bj-PRO-10c concentrations (0.01 to
3 mM) on NO production of HUVEC-PE following exposure to
the peptide for 24 h at 37uC. Bj-PRO-10c dose-dependently
augmented NO production in HUVEC-PE reaching maximal
responses (83% of NO levels of normal HUVEC) at 0.3 mM
peptide concentration (Figure 1).
Increased L-arginine production by endothelial cells in
the presence of Bj-PRO-10c
Bj-PRO-10c was recently described as an activator of ASS
activity, the step-limiting enzyme in the L-arginine biosynthesis in
the NO-citrulline cycle for NO production in the endothelium
[20]. In the same work, authors also showed that the peptide
caused an increase in L-arginine production in a kidney cell line
(HEK293 cells) [20]. L-arginine in endothelial cells is likely to play
a critical role in the control of the systemic blood pressure and the
inflammatory process, both affected in preeclampsia [16,17]. We
have observed that the basal L-arginine production levels in
HUVEC-PE were 25% lower than in HUVEC (data not shown).
In addition, 24 h incubation of the endothelial cells with 0.3 mM
Bj-PRO-10c increased L-arginine production by HUVEC and
HUVEC-PE by 104% and 118%, respectively (Figure 2).
Decreased superoxide production in HUVECs-PE in the
presence of Bj-PRO-10c
Limited bioavailability of NO, either because of a decreased
formation of NO due to low viability of substrate for NOS, or
Figure 1. Bj-PRO-10c-induced NO production in HUVEC-PE.
HUVEC-PE cultures were incubated in serum-free medium for 24 h with
increased concentrations of Bj-PRO-10c. Control experiments were
made with HUVEC in the absence of Bj-PRO-10c. NO products (NOx) of
untreated HUVEC, HUVEC-PE and Bj-PRO-10c-treated HUVEC-PE were
measured in by a chemiluminescence assay. Basal NO production by
HUVEC-PE was considered as 100%. The shown data are mean values
normalized for protein content 6 S.E. of six experiments. ** P,0.01 and
*** P,0.001 compared to untreated HUVEC-PE.
doi:10.1371/journal.pone.0023680.g001
Figure 2. Bj-PRO-10- induced L-arginine production in endo-
thelial cells. HUVEC and HUVEC-PE were incubated in serum-free
medium in the absent or presence of Bj-PRO-10c. The medium was
collected, and the cells were lysed for determination of L-arginine levels
by HPLC analysis. L-Arginine production levels in the absence of Bj-PRO-
10c were considered as 100%. The data are presented as mean values
normalized for number of cells 6 S.E. of three independent
experiments. ** P,0.01 compared to basal production.
doi:10.1371/journal.pone.0023680.g002
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increased scavenging of NO by superoxide, can result in reduced
vasodilatation or induce inflammatory processes observed in
preeclampsia [15,21]. We have previously shown that Bj-PRO-
10c is able to promote substantial increase of L-arginine and NO
production in HUVEC-PE. We then hypothesized whether a
likely improvement of the availability of NO induced by Bj-PRO-
10c would reduce the oxidative stress of the endothelial cells of
preeclamptic women. The results presented in Figure 3 demon-
strate that the production of superoxide by HUVEC-PE was 50%
higher than in HUVEC. In Bj-PRO-10c-treated HUVEC-PE
superoxide production was substantially reduced by approximately
50%, while Bj-PRO-10c did not elicit any changes in superoxide
levels in HUVEC from normotensive women (Figure 3). The
results obtained herein confirm that this peptide exerts protective
functions against preeclampsia-related accumulation of reactive
oxygen species.
Characterization of Bj-PRO-10c-induced [Ca2+]i transients
in HUVEC and HUVEC-PE
Endothelial NOS (eNOS) is a Ca2+-dependent enzyme that
catalyzes NO formation in the endothelium, whose activity is
decreased in preeclampsia [14,15]. Therefore, increases in [Ca2+]i
are important for NO production by endothelial cells. Bj-PRO-
10c-induced elevations of [Ca2+]i in both HUVEC and HUVEC-
PE, reaching peak values at 1 mM peptide concentration
(Figure 4A). Mechanism of induction of [Ca2+]i fluxes in HUVEC
and HUVEC-PE by Bj-PRO-10c were investigated using specific
inhibitors of G-protein coupled receptors and their signal
transduction (Figure 4B). Pretreatment with 100 ng/ml of
pertussis toxin, an inhibitor of Gi/o-protein-coupled receptor
activation, did not affect Bj-PRO-10c-induced [Ca2+]i mobiliza-
tion, neither in HUVECs nor in HUVECs-PE, while preincuba-
tion with U-73122, a specific inhibitor of PLC-c activity, inhibited
the Bj-PRO-10c-promoted [Ca2+]i increase. Moreover, pretreat-
ment of HUVEC and HUVEC-PE with 50 mM ryanodine, used
for inhibition of calcium-induced calcium release (CICR) mech-
anisms, resulted in a significant reduction of Bj-PRO-10c-evoked
[Ca2+]i transients. Bj-PRO-10c-provoked [Ca
2+]i responses were
affected in the presence of EGTA and BAPTA-AM, chelating
extra- and intracellular calcium, respectively. Bj-PRO-10-c-
induced responses were also blocked following preincubation of
cells with thapsigargin, inhibiting endoplasmic reticulum Ca2+-
ATPase [22] and leading to depletion of intracellular calcium
stores, confirming the participation of both, calcium influx into the
cell and intracellular calcium stores.
Modulation of ASS and eNOS expression by Bj-PRO-10c
Western-blot analysis confirmed that eNOS and ASS expression
in HUVEC-PE was lower when compared to HUVEC (Figure 5A
and B). When HUVEC and HUVEC-PE were pretreated for 24 h
with Bj-PRO-10c, eNOS expression in HUVEC-PE was two-fold
increased, when compared to expression levels of non-treated
control HUVEC-PE. In the presence of the peptide, eNOS levels
in HUVEC-PE were similar to those of HUVEC from
normotensive pregnant women. However, ASS expression in
HUVEC-PE and both eNOS and ASS expression in Bj-PRO-10c-
treated HUVEC were not significantly different from non-treated
cells (Figure 5A and B).
Discussion
Preeclampsia is a syndrome in women occurring during
pregnancy and is characterized by elevated blood pressure and
proteinuria. The development of preeclampsia is accompanied by
increased vascular reactivity as response to vasoconstrictors,
decreased NO production, and increased accumulation of
superoxide [23]. The results presented here provide important
information regarding the use of Bj-PRO-10c as a possible model
for the development of a therapeutic modality to treat the
condition preeclampsia-eclampsia. Bj-PRO-10c is an oligopeptide
endowed with antihypertensive activity that decreases blood
pressure in hypertensive but not in normotensive rats [24].
Recently, our group demonstrated that this peptide positively
modulated ASS activity in vitro and in vivo, thereby increasing NO
production [20]. This fact prompted us to propose the use of Bj-
PRO-10c for treatment of preeclampsia, since this peptide should
not affect blood pressure of the fetus, a problem with drugs
currently used for minimizing health problems arising from
preeclampsia. However, the peptide could correct the deficiency
in NO production observed in specific tissues of preeclamptic
pregnancy, as observed in the present work in human umbilical
vein endothelial cells (HUVEC).
Guerreiro and co-workers showed that Bj-PRO-10c led to
increases the production of NO in HUVEC due to activation of
the ASS, the rate-limiting enzyme for the continuous regeneration
of L-arginine from L-citrulline in the NO-citrulline cycle, thus
providing NOS with sustained supply of substrate [20]. In the
present study, we found that NO production of HUVEC-PE is
lower than that of HUVEC, being in agreement with many studies
suggesting deficiency in NO production by endothelial cells in
preeclampsia [9,15]. Bj-PRO-10c was able to increase NO
production in HUVEC-PE to normal physiological levels.
Bj-PRO-10c as is a positive modulator of ASS activity [20], was
able to enhance of ASS activity of total protein of HUVEC lysed
(data not shown), reflecting increased L-arginine and NO
production in both, HUVEC and HUVEC-PE.
Production of reactive oxygen species, primarily superoxide
anions, goes along with a deficit in NO biosynthesis considered as
a determining factor in the pathophysiology of preeclampsia
Figure 3. Inhibition of superoxide production in HUVEC-PE by
Bj-PRO-10c. HUVEC and HUVEC-PE were pre-incubated in serum-free
medium for 24 h in the absence or presence of 1 mM Bj-PRO-10c. After
this period of pre-incubation the cells were treated with the
superoxide-sensitive fluorescent probe and emitted fluorescence was
measured by using an automated plate reader. Superoxide production
by HUVEC was considered as 100%. The data are expressed as the mean
values normalized for number of cells 6 S.D. of three independent
experiments. *** P,0.001 compared to HUVEC basal production and
##P,0.01 compared to HUVEC-PE basal production.
doi:10.1371/journal.pone.0023680.g003
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[15,21]. The superoxide anion is produced by uncoupling of NOS
due to the lack of its natural substrate L-arginine. In preeclampsia,
excessive production of superoxide is explained by increased
activity and expression of the enzyme arginase, which competes
with eNOS for its substrate L-arginine. It was recently demon-
strated by Sankaralingam and colleagues [25] that arginase
Figure 4. Characterization of Bj-PRO-10c-induced [Ca2+]i elevations in endothelial cells. A. Changes of maximal peak heights of [Ca
2+]i
responses induced by increasing concentrations of Bj-PRO-10c (0.01–3 mM) were measured in HUVEC and HUVEC-PE by microfluorimetry. B.
Evaluation of Bj-PRO-10c-induced [Ca2+]i transients in HUVEC and HUVEC-PE in the presence of chelating agents and specific inhibitors of Ca
2+
signaling. Cells were pre-incubated for 5 or 30 min with 10 mM EGTA or 10 mM BAPTA (extracellular and intracellular Ca2+ chelators), respectively.
Cells also were pre-treated for 18 h with 100 ng/ml pertussis toxin (PTX) for inhibition of Gi/o-protein mediated receptor responses and for 30 min
with U73122, a PLC-c inhibitor. Calcium release from intracellular stores was inhibited by a 30 min pre-incubation of cells with 200 ng/ml
thapsigargin. The participation of ryanodine-sensitive calcium stores was studied following 30 min pretreatment of cells with 50 mM ryanodine.
* P,0.05, ** P,0.01 and *** P,0.001 compared to Bj-PRO-10c control data obtained in the absence of pre-treatment. The shown data are mean
values 6 S.E. of five independent experiments.
doi:10.1371/journal.pone.0023680.g004
Figure 5. Analysis of eNOS and ASS protein levels in HUVEC and HUVEC-PE. Endothelial cells were incubated for 24 h in serum-free
medium in the absence (control) or presence of 1 mM Bj-PRO-10c. Then, cells were lysed and 50 mg of cell homogenate proteins were used for
Western-blot analysis as detailed in Materials and Methods. Relative quantification of eNOS (A) and ASS (B) expression levels was obtained by
densitometry scanning. b-Actin immunostaining was used as endogenous control for normalizing of protein expression. Data (mean values 6 S.E.)
are representative for three independent experiments. * P,0.05 compared to untreated control HUVEC-PE.
doi:10.1371/journal.pone.0023680.g005
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activity was increased in the vasculature of women with
preeclampsia, resulting in enhanced superoxide production. Kim
and colleagues [26] demonstrated that inhibition of arginase
promoted the recoupling of eNOS, failing to produce the
superoxide anion and decreasing oxidative stress. Although Bj-
PRO-10c did not affect arginase activity (data not shown), this
peptide recoupled eNOS and consequently reduced the produc-
tion of superoxide by HUVEC-PE, thanks to its ability of
increasing ASS activity [20] and inducing L-arginine production.
The eNOS is probably inactive at basal Ca2+ levels of resting cells,
and is only activated when the intracellular calcium concentration
([Ca2+]i) is elevated [27,28]. The activation of eNOS occurring
through the formation of Ca2+/calmodulin complexes is respon-
sible for triggering the transfer of electrons from the C-terminal to
the N-terminal portion of eNOS [29,30].
Recently it was demonstrated that Bj-PRO-10c is capable of
inducing [Ca2+]i mobilization in neurons, mediated by a receptor
coupled to Gi/0-protein, followed by a calcium-induced calcium
release (CICR) mechanism [18]. In the present paper we have shown
that Bj-PRO-10c also induced [Ca2+]i fluxes in endothelial cells
with similar mechanisms to those described in neuronal cells [18].
The depletion of intracellular Ca2+ stores by preincubation with
thapsigargin, an inhibitor of Ca2+-ATPase of the endoplasmic
reticulum [22], resulted in an almost complete loss of Bj-PRO-10c-
induced [Ca2+]i elevations. In addition, Bj-PRO-10c-induced [Ca
2+]i
transients were significantly reduced in the absence of extracellular
calcium. The preincubation of HUVECs with ryanodine, an
inhibitor of CICR mechanism [31], significantly decreased the Bj-
PRO-10c-induced [Ca2+]i response. U-73122, a specific inhibitor of
phospholipase C-b (PLC-b) activtiy [32], was used to determine the
involvement of this enzyme in the signaling pathway of Bj-PRO-10c.
Bj-PRO-10c-induced [Ca2+]i increase was affected by incubation
with the PLC-b inhibitor suggesting the involvement of IP3 formation
catalyzed by the phospholipase. The preincubation of HUVECs with
pertussis toxin, an inhibitor of protein Gi or Go [33], did not cause
significant reduction in Bj-PRO-10c-induced [Ca2+]i transient,
suggesting that the putative receptor of Bj-PRO-10c did not depend
on Gi nor Go protein activation.
The data presented herein show that Bj-PRO-10c-induced [Ca2+]i
transients were mediated by influx of calcium, followed by calcium
release from intracellular stores sensitive to ryanodine, known as
CICR mechanism. Moreover, Bj-PRO-10c did not promote an
increase in [Ca2+]i in smooth muscle cells (data not shown), featuring
a specificity of Bj-PRO-10c on endothelial cells. Such increase of
[Ca2+]i in smooth muscle cells would result in vasoconstriction and be
contradictory to anti-hypertensive actions of Bj-PRO-10c [34].
It is known that the development of preeclampsia involves
changes in expression levels of enzymes participating in NO
metabolism [9,25]. Levels of eNOS, the enzyme responsible for NO
synthesis in the endothelium from L-arginine, are decreased in
HUVEC-PE [9] together with the ASS expression, an observation
reported here for the first time. Low eNOS and ASS protein levels
could explain why NO production is impaired in HUVEC-PE.
Therefore, a correction of eNOS and ASS expression rates to
normal levels could contribute to the treatment of preeclampsia.
Indeed, eNOS expression of HUVEC-PE increased significantly in
the presence of Bj-PRO-10c. Although the peptide did not increase
the ASS expression, it augmented the activity of this enzyme [20],
thereby possibly compensating reduced protein levels. Furthermore,
treatment of HUVEC with Bj-PRO-10c did not alter eNOS
expression. Thus, although Bj-PRO-10c-induced signaling path-
ways in HUVEC and HUVEC-PE are the same, due to slight
differences in signal intensity in HUVEC-PE, Bj-PRO-10c-
promoted calcium fluxes may induce distinct pathways [35] leading
to an increase in eNOS expression in HUVEC-PE, which are not
activated in HUVEC from normotensive women.
Together, our work has identified eNOS and ASS as targets of Bj-
PRO-10c for NOS production in HUVEC from pregnant women.
In the presence of the peptide, eNOS expression and activity as well
as ASS activity are enhanced increasing NO levels to those of
normotensive women. Since Bj-PRO-10c promoted NO production
in HUVEC from patients suffering from the disorder and not in
normotensive pregnant women, it is suggested that Bj-PRO-10c
would induce its anti-hypertensive effect in mothers with pre-
eclampsia, such properties may initiate the development of novel
specific therapeutics for the treatment of preeclampsia.
Materials and Methods
Ethics Statement
The study received prior approval from the Hospital Municipal
Maternidade-Escola Dr. Ma´rio de Moraes A. Silva, Sa˜o Paulo,
Brazil (01/2009) and Universidade Federal de Sa˜o Paulo, Sa˜o
Paulo, Brazil (1956/2008) and written informed consent was
obtained from women donors of umbilical cord.
Synthesis and purification of Bj-PRO-10c
Bj-PRO-10c (,ENWPHPQIPP), was synthesized using an
automated PSSM-8 peptide synthesizer (Shimadzu Corp.,
Chiyoda-ku Kyoto, Japan) by a stepwise solid-phase method using
N-9-fluorenylmethoxycarbonyl (Fmoc) chemistry [36]. The Bj-
PRO-10c was purified on a reversed-phase column (ODS-C18,
Shimadzu, 20 mm6250 mm column) coupled to a HPLC system
equipped with the binary pump LC-6AD and the SPD-10AV UV-
Vis detector. Molecular mass and purity of the synthesized peptide
were confirmed by MALDI-TOF mass spectrometry (Amersham
Biosciences, Uppsala, Sweden) [18].
Collection and establishment of human umbilical vein
endothelial cells (HUVECs)
Umbilical cords were collected from normotensive pregnant
(n = 8) and pregnants suffering from preeclampsia (n = 9).
Preeclampsia was defined as new-onset hypertension
(.140690 mmHg) associated with proteinuria .0.3 g/24 h. In
addition, all patients in this study had early-onset preeclampsia
(,34 gestational weeks) and proteinuria was higher than 1 g/24 h
in all cases. All women in the control group had normal pregnancy
and delivered at term. The umbilical cords were placed on
aluminum foils, checked for any injuries and then cleaned
externally with 70% ethanol and sterile gauze. We conducted a
cross court at its end, where it was located in the umbilical vein for
cannulation. Then, with a key three-way connected to a 20 ml
syringe containing sterile saline solution, the vein was washed at
least three times to remove traces of blood contained within it.
Immediately following the washing steps, the umbilical cord was
treated for 15 min at 37uC with collagenase type IV (Worthington
Biochemical Corp., NJ, USA) using 1 mg/ml enzyme for each cm
of umbilical cord. The solution containing collagenase was
transferred into a sterile Falcon tube followed by addition of fetal
calf serum to obtain a final concentration of 10% in order to
neutralize collagenase. Once neutralized, the solution was
centrifuged for 10 min at 3,000 g at 4uC; the supernatant was
discarded and cells were resuspended in 2 ml of complete culture
medium (Human Endothelial culture medium supplemented with
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, 1%
gentamicin and 1% sodium pyruvate). The cell suspension was
placed in a bottle previously treated with a solution of 1% gelatin.
The cells were incubated at 37uC in a water-saturated atmosphere
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of 5% CO2. The culture medium was exchanged on the next day,
and then every three days, supplementing with 10 ng/ml
epidermal growth factor (EGF) and 20 ng/ml basic fibroblast
growth factor (bFGF). Immunohistochemical analysis using anti-
CD31 FITC-conjugated antibodies was performed for character-
ization of endothelial cells.
Chemiluminescence Assay for Measurement of Nitric
Oxide Products (NOx)
For the quantification of NO, 16106 HUVECs were plated in 6
wells plates with culture medium supplemented with fetal calf
serum. After the period of cell adhesion, the culture medium was
replaced by medium without serum, followed by 24 h incubation
with 1 mM Bj-PRO-10c. Then the culture medium was collected
and centrifuged for 5 min at 21,000 g to eliminate possible cellular
debris, and the supernatant was collected for analysis of NOx. The
cells were washed with PBS, lysed for 30 min in ice-cold RIPA
buffer (50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 1%
Nonidet P-40 (NP- 40), 0.5%, sodium deoxycholate, 0.1% SDS,
1 mM DTPA and 10 mM N-ethylmaleimide) and centrifuged for
15 min at 21,000 g and 4uC. NOx determination was carried out
as described elsewhere [37]. Intracellular and extracellular media
were directly injected into a vessel containing a saturated solution
of vanadium (III) chloride in 1N HCl maintained at 90uC. Under
these conditions, all nitric oxide-derived products (nitrate, nitrite,
nitrosothiol, nitrosamines, and iron-nitrosyl complexes) were
reduced and compared with those of standard solutions of nitrate
under the same experimental conditions.
Determination of L-arginine concentration in endothelial
cells
L-arginine levels in HUVEC and HUVEC-PE were determined
as described elsewhere [20]. Briefly, 16106 cells in serum-free
medium were incubated for 24 h at 37uC with 0.3 mM of Bj-PRO-
10c. Both, extra and intracellular L-arginine concentrations were
determined by amino acid detection analysis using a C18
analytical HPLC column (250 mm, 4.6 mm, 5 mm; Merck).
Superoxide production
Endothelial cell cultures were transferred into 96 black-well plates
with clear bottom (Costar, London, UK) with a density of 56104 cells
per well in serum-supplemented medium to cell adhesion to the plastic
surfaces. Then the culture medium was replaced by serum-free
medium followed by exposure of cells for 24 h to 1 mM Bj-PRO-10c.
Superoxide production was detected by oxidation of dihydroethidium
to a specific fluorescent product, oxi-ethidium using a Dihydroethidium
kit (Invitrogen, CA, USA) [38]. Following a 30-min treatment with the
superoxide sensitive probe, the cells were washed twice with buffer
(10 mM HEPES, pH 7.4, 144 mM NaCl, 2 mM CaCl2, 1 mM
MgCl2, 5 mM KCl, 10 mM D-glucose). Reading of fluorescence was
performed using the automated plate reader FlexStation 3 (Molecular
Devices, CA, USA) using excitation and emission wavelengths of
530 nm and 620 nm, respectively.
Calcium measurements by microfluorimetry
For determination of changes in cytosolic calcium concentration
([Ca2+]i) by microfluorimetry using Flexstation 3, HUVECs were
transferred into 96 black-well plates with clear bottom (Costar,
London, UK) at a density of 56104 cells per well in serum-free
medium. The cells were then loaded for 60 min at 37uC with the
Flexstation Calcium Kit in the presence of 2.5 mM probenecid, as
described [18,39]. The fluorescence was monitored before and after
the addition of increasing concentrations of Bj-PRO-10c. Samples
were read for 120 seconds at 1.52 s intervals with a total of 79 read-
outs per well. Fluorescence of samples was excited at 485 nm, and
fluorescence emission was detected at 525 nm. Responses were
measured by the peak fluorescence intensity following agonist
application compared to baseline fluorescence intensities.
Determination of eNOS and ASS levels by Western-blot
HUVECs were cultured in serum-containing medium to reach
80% of confluence. Then, cells were exposed for 24 h to 1 mM Bj-
PRO-10c in serum-free medium. After this incubation period, cells
were lysed for 20 min in ice-cold RIPA buffer and centrifuged for
5 min at 21,000 g. Fifty mg of each protein sample was separated by a
10% SDS-PAGE. Proteins were transferred from the gel to a
nitrocellulose membrane in 0.38 M Tris-HCl, 0.18 M glycine and
20% methanol under constant voltage of 30 V for 12 hours. The
nitrocellulose membrane was incubated in TBS-Tween (20 mM
Tris-HCl pH 7.4, 0.15 M NaCl and 0.05% Tween) and 5% BSA,
followed by three washing steps with TBS-Tween. The membrane
was incubated with a 1:500 dilution of anti-ASS mouse (BD
Transduction Laboratories, NJ, USA), a 1:5,000 dilution of anti-
eNOS rabbit (Stressgen Biotechnologies, CA, USA) or a 1:7,500 of
dilution of anti-b-actin mouse primary antibodies (Santa Cruz
Biotechnology Inc, CA, USA). Following addition of alkaline
phosphatase-conjugated secondary antibodies (Promega Corp., WI,
USA), immunostaining was revealed with AP solution (5 M NaCl,
1 M Tris-HCl pH 9.5, 1 M MgCl2) containing BCIP (5-bromo-4-
chloro-3-indolylphosphate) and NBT (nitro blue tetrazolium).
Density of immunostaining was estimated using the ImageJ program
(National Institutes of Health, USA). For relative quantification of
ASS expression levels, staining intensities were compared to those of
b-actin, whose expression should not vary under the used
experimental conditions.
Statistical Analysis
Statistical analysis was performed using one-way ANOVA
followed by Boferroni’s post-test, employing the GraphPad Prism 5
software. Differences were considered significant when *P,0.05,
**P,0.01 and ***P,0.001.
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